Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 6, Number 4, August 2014, pages 252-260


Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy

Figure

Figure 1.
Figure 1. The doses of VCR (A), adriamycin (B), cyclophosphamide (C) and prednisolone (D) in the early-onset VIPN (-) group (n = 27) and the early-onset VIPN (+) group (n = 14). ADR: adriamycin; CPA: cyclophosphamide; PSL: prednisolone.

Tables

Table 1. Characteristics of the Study Population of 41 Patients Treated With an R-CHOP or R-CHOP-Like Regimen for the First Time
 
FactorEarly-onset VIPN (-) (n = 27)Early-onset VIPN (+) (n = 14)P value
Means ± SD or no. of patients (%)Means ± SD or no. of patients (%)
aFisher’s exact probability test. bMann-Whitney U test. cStudent’s t-test.
Peripheral neuropathy
  Grade 111 (79)
  Grade 22 (14)
  Grade 31 (7)
  Grade 40 (0)
Gender (male/female)16/115/90.20a
Age, median (range) (years)68 (41 - 87)53 (34 - 72)0.0064b
Body weight59.9 ± 10.456.2 ± 11.30.31c
Aspartate aminotransferase28.9 ± 12.422.0 ± 11.60.59c
Alanine aminotransferase15.5 ± 8.125.3 ± 13.70.12c
γ-glutamyl transpeptidase33.8 ± 24.948.5 ± 34.70.57c
Total bilirubin0.60 ± 0.240.67 ± 0.240.37c
Creatinine clearance97.9 ± 40.3112.9 ± 18.50.20c
Diabetes mellitus requiring medication4 (15)1 (7)0.66a
Lymphoma type
  Diffuse large B-cell lymphoma15 (56)9 (64)0.74a
  Follicular lymphoma7 (26)2 (14)0.70a
  Others5 (18)3 (22)1.00a
Regimen
  Normal-dose chemotherapy17 (63)14 (100)0.0085a
    R-CHOP14 (52)12 (86)0.044a
    R-CVP3 (11)2 (14)1.00a
  Reduced-dose chemotherapy
    R-THP-COP10 (37)0 (0)0.0085a
Concomitant use of aprepitant9 (33)10 (71)0.026a

 

Table 5. Risk Factors for Developing Early-Onset VIPN by Multivariate Logistic Regression Analysis
 
FactorOdds ratio95% CIP value
Age ≥ 65 years0.900.13 - 6.380.92
VCR dose ≥ 1.9 mg15.291.14 - 205.660.039
Concomitant use of aprepitant6.091.15 - 32.110.033